Sector Chart Allogene Therapeutics, Inc.

Stocks

ALLO

US0197701065

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:22:02 10/08/2026 +04			5-day change	1st Jan Change
2.045 ^USD	+1.74%		+11.36%	+49.56%

07-29	Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations	MT
07-29	Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Bio Therapeutic Drugs

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
ALLOGENE THERAPEUTICS, INC.	694M	-	-	-	-	-
WUXI APPTEC CO., LTD.	68.12B
ARGENX SE	55.18B
INSMED INCORPORATED	28.63B					-
WUXI BIOLOGICS (CAYMAN) INC.	23.99B
BIONTECH SE	23.53B					-